These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 26472454)
1. Hapten-Binding Bispecific Antibodies for the Targeted Delivery of SiRNA and SiRNA-Containing Nanoparticles. Thorey IS; Grote M; Mayer K; Brinkmann U Methods Mol Biol; 2016; 1364():219-34. PubMed ID: 26472454 [TBL] [Abstract][Full Text] [Related]
2. Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery. Dengl S; Sustmann C; Brinkmann U Immunol Rev; 2016 Mar; 270(1):165-77. PubMed ID: 26864111 [TBL] [Abstract][Full Text] [Related]
3. Nanocell targeting using engineered bispecific antibodies. Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM MAbs; 2015; 7(1):53-65. PubMed ID: 25523746 [TBL] [Abstract][Full Text] [Related]
4. Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies. Schneider B; Grote M; John M; Haas A; Bramlage B; Ickenstein LM; Jahn-Hofmann K; Bauss F; Cheng W; Croasdale R; Daub K; Dill S; Hoffmann E; Lau W; Burtscher H; Ludtke JL; Metz S; Mundigl O; Neal ZC; Scheuer W; Stracke J; Herweijer H; Brinkmann U Mol Ther Nucleic Acids; 2012 Sep; 1(9):e46. PubMed ID: 23344238 [TBL] [Abstract][Full Text] [Related]
5. Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies. Parker CL; Jacobs TM; Huckaby JT; Harit D; Lai SK mBio; 2020 Jan; 11(1):. PubMed ID: 31964730 [TBL] [Abstract][Full Text] [Related]
6. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309 [TBL] [Abstract][Full Text] [Related]
7. Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. Bäumer N; Appel N; Terheyden L; Buchholz F; Rossig C; Müller-Tidow C; Berdel WE; Bäumer S Nat Protoc; 2016 Jan; 11(1):22-36. PubMed ID: 26633129 [TBL] [Abstract][Full Text] [Related]
8. Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates. Mehrabadi FS; Adelmann J; Gupta S; Wedepohl S; Calderón M; Brinkmann U; Haag R Curr Cancer Drug Targets; 2016; 16(7):639-49. PubMed ID: 26853135 [TBL] [Abstract][Full Text] [Related]
9. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586 [TBL] [Abstract][Full Text] [Related]
10. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes. Choi KM; Jang M; Kim JH; Ahn HJ Biomaterials; 2014 Aug; 35(25):7121-32. PubMed ID: 24854094 [TBL] [Abstract][Full Text] [Related]
11. Dendrimer Nanovectors for SiRNA Delivery. Liu X; Peng L Methods Mol Biol; 2016; 1364():127-42. PubMed ID: 26472447 [TBL] [Abstract][Full Text] [Related]
12. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion. Lu D; Zhu Z Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843 [TBL] [Abstract][Full Text] [Related]
13. Magnetic nanoparticle and magnetic field assisted siRNA delivery in vitro. Mykhaylyk O; Sanchez-Antequera Y; Vlaskou D; Cerda MB; Bokharaei M; Hammerschmid E; Anton M; Plank C Methods Mol Biol; 2015; 1218():53-106. PubMed ID: 25319646 [TBL] [Abstract][Full Text] [Related]
14. Antibody-mediated delivery of siRNAs for anti-HIV therapy. Kim SS; Subramanya S; Peer D; Shimaoka M; Shankar P Methods Mol Biol; 2011; 721():339-53. PubMed ID: 21431696 [TBL] [Abstract][Full Text] [Related]
15. Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA. Choi KM; Choi SH; Jeon H; Kim IS; Ahn HJ ACS Nano; 2011 Nov; 5(11):8690-9. PubMed ID: 21985460 [TBL] [Abstract][Full Text] [Related]
16. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918 [TBL] [Abstract][Full Text] [Related]
17. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Pittella F; Zhang M; Lee Y; Kim HJ; Tockary T; Osada K; Ishii T; Miyata K; Nishiyama N; Kataoka K Biomaterials; 2011 Apr; 32(11):3106-14. PubMed ID: 21272932 [TBL] [Abstract][Full Text] [Related]
18. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. Wang XL; Xu R; Lu ZR J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104 [TBL] [Abstract][Full Text] [Related]
19. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Gu J; Ghayur T Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980 [TBL] [Abstract][Full Text] [Related]
20. A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies. Brard PY; Karacay H; Stein R; Sharkey RM; Mattes MJ; Chang CH; Rossi EA; McBride WJ; Goldenberg DM Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5564s-5571s. PubMed ID: 17875790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]